

The following fusogenic peptides disclosed in DE 196 49 645.4, are listed on page 10, lines 30-64:

- (1) peptide containing the peptide GLFEALLELLESLWELLLEA (Gottschalk *et al.*, *Gene Ther.* 3: 448 (1996));
- (2) peptide containing the peptide AALAEA[LAEA]₄LAAAGC (Acm) (Wang *et al.*, *Technol. Advances in Vector Syst. For Gene Ther.*, May 6-7, 1996, Coronado, IBC Conference);
- (3) peptide containing the peptide FAGV-VLAGAALGVAAAAQI of the fusion protein of measles-virus (Yeagle *et al.*, *Biochem. Biophys. Acta* 1065, 49 (1991));
- (4) peptide containing the peptide GLFGAIAGFIEGGWWGMIDG of the HA2 proteins of Influenza A (Lueneberg *et al.*, *J. Biol. Chem.* 270, 27606 (1995));
- (5) peptide containing the peptide GLFGAIAGFIENGWEGMIDG
GLFGAIAGFIENGWEGMIDG (Burger *et al.*, *Biochem.* 30, 11173 (1991)) or
the peptide GLFGAIAGFIE; ALFGAIAGFIE; LFLGAIAGFIE;
LLLGAIAAGFIE; LILGAIAAGFIE; GIFGAIAAGFIE; GLLGAIAAGFIE;
GLFAAIAAGFIE; GLFEAIAAGFIE; GLFGAMAGFIE; GLFGAIAAGLIE or the
peptide GLFGAIAAGFIV (Steinhauer *et al.*, *J. Virol.* 69, 6643 (1995));
- (6) the peptide GLFEAIAEFIEGGWEGLIEG; and
- (7) the peptide GLLEALAELEGGWEGLLEG (Ishiguro *et al.*, *Biochem.* 32, 9792 (1993)).

The following target cell specific ligands are disclosed in DE 196 49 545.4 and listed on page 3, lines 46 through page 9, line 63, thereof:

- (1) antibody fragments directed against membrane structures of endothelial cells such as, for example, Burrows *et al.* (Pharmac. Ther. 64, 155 (1994), Hughes *et al.* (Cancer Res. 49, 6214 (1989) and Murayama *et al.* (PNAS-USA 87, 5744 (1990)) specially antibodies against VEGF-receptors. (disclosed in DE 196 49 645 A1, p. 5, lines 19-22);
- (2) antibodies or antibody fragments directed against membrane structures of immune cells, such as described in Powelson *et al.*, Biotech. Adv. 11, 725 (1993) or antibodies or antibody fragments that bind with their antigen binding part the FC- \square FC- \square or FC- \square Rojanasakul *et al.* Pharm. Res. 11, 1731 (1994), (disclosed in DE 196 49 645 A1, p. 5, lines 50-61);
- (3) antibodies or antibody fragments directed against membrane structures of muscle cells, such as the antibody 10F3, antibody against actin, antibody against angiotensin II receptors or antibodies against receptors of growth factors (disclosed in DE 196 49 645 A1, p. 6, lines 48-56);
- (4) antibodies or antibody fragments directed against membrane structures of tumor cells, such antibodies are described in Sedlacek *et al.*, Contrib. to Oncol. 32, Karger Publisher, Munich (1998) and Contrib. to Oncol. 43, Karger Publisher, Munich (1992) (disclosed in DE 196 49 645 A1, page 9, lines 50-54).

The gene construct-specific ligands disclosed in DE 196 49 645.4 and listed on page 11, line 55 through page 13, line 40 thereof are:

(1) antibodies directed against epitopes newly introduced into DNA such as antibodies directed against methylated DNA, antibodies against O⁶-ethyl deoxyguanosine, antibodies against N⁵-methyl-N⁵-formyl-2,5,6,-triamino-4-hydroxy-pyrimidine, antibodies against N⁷-ethyl guanine, antibodies against O⁶-methyl-2'-deoxyguanosine, antibodies against O⁶-ethyl-2'-deoxyguanosine, antibodies against O⁶-N-butyl-2'-deoxyguanosine, antibodies against O⁶-isopropyl-2'-deoxyguanosine, antibodies against O⁴-methyl-2'-deoxyguanosine or antibodies against O⁴-ethyl-2'-deoxyguanosine, antibodies against methylated DNA, especially against N⁶-methylated adenine.

- (2) antibodies directed against envelope proteins or viruses such as for example
- murine leukemia virus, the antibody being preferably directed against envelope proteins gp70 and p15,
 - HIV,
 - herpes simplex virus, the antibody being preferably directed against glycoprotein B, glycoprotein H, glycoprotein L,
 - cytomegalovirus, the antibody being preferably directed against glycoprotein B (gpB),
 - adeno-associated virus,
 - minute virus of mice,
 - antibodies against adeno-associated virus, the antibody being preferably directed against Cap- and Rep-proteins,
- cytomegalovirus, the antibody being preferably directed against glycoprotein B (gpB).

Please insert the following new paragraphs between the first and second paragraphs on Page 10 of the specification

sub E'

--The following fusogenic peptides disclosed in DE 196 49 645.4, are listed on page 10, lines 30-64:

- (1) peptide containing the peptide GLFEALLESLESLWELLLEA (Gottschalk *et al.*, *Gene Ther.* 3: 448 (1996));
- (2) peptide containing the peptide AALAEA[LAEA]₄LAAAGC (Acm) (Wang *et al.*, *Technol. Advances in Vector Syst. For Gene Ther.*, May 6-7, 1996, Coronado, IBC Conference);
- (3) peptide containing the peptide FAGV-VLAGAALGVAAAAQI of the fusion protein of measles-virus (Yeagle *et al.*, *Biochem. Biophys. Acta* 1065, 49 (1991));
- (4) peptide containing the peptide GLFGAIAGFIEGGWWGMIDG of the HA2 proteins of Influenza A (Lueneberg *et al.*, *J. Biol. Chem.* 270, 27606 (1995));
- (5) peptide containing the peptide GLFGAIAGFIENGWEGMIDG
GLFGAIAGFIENGWEGMIDG (Burger *et al.*, *Biochem.* 30, 11173 (1991)) or
the peptide GLFGAIAGFIE; ALFGAIAGFIE; LFLGAIAGFIE;
LLLGAIAGFIE; LILGAIAGFIE; GIFGAIAGFIE; GLLGAIAGFIE;
GLFAAIAGFIE; GLFEAIAGFIE; GLFGAMAGFIE; GLFGAIAGLIE or the
peptide GLFGAIAGFIV (Steinhauer *et al.*, *J. Virol.* 69, 6643 (1995));
- (6) the peptide GLFEAIAEFIEGGWEGLIEG; and
- (7) the peptide GLLEALAELEGGWEGLLEG (Ishiguro *et al.*, *Biochem.* 32, 9792 (1993)).

The following target cell specific ligands are disclosed in DE 196 49 545.4 and listed on page 3, lines 46 through page 9, line 63, thereof:

- D,
- (1) antibody fragments directed against membrane structures of endothelial cells such as, for example, Burrows *et al.* (Pharmac. Ther. 64, 155 (1994), Hughes *et al.* (Cancer Res. 49, 6214 (1989) and Murayama *et al.* (PNAS-USA 87, 5744 (1990)) specially antibodies against VEGF-receptors. (disclosed in DE 196 49 645 A1, p. 5, lines 19-22);
 - (2) antibodies or antibody fragments directed against membrane structures of immune cells, such as described in Powelson *et al.*, Biotech. Adv. 11, 725 (1993) or antibodies or antibody fragments that bind with their antigen binding part the FC- γ FC- ϵ or FC- μ Rojanasakul *et al.* Pharm. Res. 11, 1731 (1994), (disclosed in DE 196 49 645 A1, p. 5, lines 50-61);
 - (3) antibodies or antibody fragments directed against membrane structures of muscle cells, such as the antibody 10F3, antibody against actin, antibody against angiotensin II receptors or antibodies against receptors of growth factors (disclosed in DE 196 49 645 A1, p. 6, lines 48-56);
 - (4) antibodies or antibody fragments directed against membrane structures of tumor cells, such antibodies are described in Sedlacek *et al.*, Contrib. to Oncol. 32, Karger Publisher, Munich (1998) and Contrib. to Oncol. 43, Karger Publisher, Munich (1992) (disclosed in DE 196 49 645 A1, page 9, lines 50-54).

The gene construct-specific ligands disclosed in DE 196 49 645.4 and listed on page 11, line 55 through page 13, line 40 thereof are:

- (1) antibodies directed against epitopes newly introduced into DNA such as antibodies directed against methylated DNA, antibodies against O⁶-ethyl deoxyguanosin,